Journal article

Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort

Joseph S Doyle, Jason Grebely, Tim Spelman, Maryam Alavi, Gail V Matthews, Alexander J Thompson, Gregory J Dore, Margaret E Hellard



Awarded by National Institutes of Health

Funding Acknowledgements

The ATAHC Study was funded by the National Institutes of Health (grant RO1 DA 15999-01). Roche Pharmaceuticals supplied financial support for pegylated-IFN alfa-2a/ribavirin use in the ATAHC Study. JD, JG, GM, AT, GD, and MH acknowledge fellowship support from the National Health and Medical Research Council. JD, TS and MH acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program (Department of Health, Victoria, Australia) to the Burnet Institute. The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. None of the funding sources had any involvement in the conduct, analysis or reporting of the study. Roche Pharmaceuticals had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.